Section Arrow
ALT.NASDAQ
- Altimmune
Quotes are at least 15-min delayed:2025/11/04 04:20 EST
Pre Market
Last
 3.93
-0.03 (-0.76%)
Bid
3.92
Ask
3.94
High 3.97 
Low 3.93 
Volume 1026 
Regular Hours
Last
 3.96
-0.09 (-2.22%)
Day High 
4.05 
Prev. Close
4.05 
1-M High
4.25 
Volume 
2.19M 
Bid
3.92
Ask
3.94
Day Low
3.925 
Open
4.03 
1-M Low
3.75 
Market Cap 
357.44M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.02 
20-SMA 3.98 
50-SMA 3.84 
52-W High 11.16 
52-W Low 2.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.18/-1.38
Enterprise Value
358.84M
Balance Sheet
Book Value Per Share
1.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.67 -0.19 -10.22%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.36 -0.07 -2.88%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.975 +0.025 +1.28%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.28 -0.16 -2.94%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.14 -0.06 -1.88%
Quotes are at least 15-min delayed:2025/11/04 04:20 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.